Firefly luciferase mRNA-LNP

Name: Firefly luciferase mRNA-LNP
Brand: MedChemExpress
SKU: HY-153229
Rating: 4.5 (1 reviews)

製品番号: HY-153229: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) containing firefly luciferase mRNA. Firefly luciferase mRNA-LNP exhibits a stable nanostructure, in which LNP plays a key role in effectively protecting and transporting mRNA to cells. Luciferase is a bioluminescent reporter gene for gene regulation and functional studies. Firefly Luciferase mRNA-LNP expresses firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Firefly luciferase mRNA-LNP is studied in research for RNA delivery, cell viability, and translation efficiency.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

容量	価格（税別）	在庫状況	数量
100 μg	$540	在庫あり	Estimated Time of Arrival: December 31
500 μg	$1620	在庫あり	Estimated Time of Arrival: December 31

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

顧客検証

•Sci Adv. 2025 Mar 28;11(13):eads2295. [Abstract]

In Vivo Imaging

: Firefly luciferase mRNA-LNP purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Mar 28;11(13):eads2295. [Abstract]; Representative in vivo imaging system images of major organs in SCI mice after being administered with firefly luciferase (FLuc) mRNA-LNPs (0.5 mg mRNA/kg). From left to right are the heart, liver, spleen, lung, two kidneys, and spinal cord. iv, intravenous; ip, intraperitoneal.

おすすめ

•関連小分子:

•関連タンパク質:

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

体外実験

Firefly luciferase mRNA-LNP (5-20 ng, 24 h) significantly increases the transfection efficiency dose-dependently in HepG2 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Firefly luciferase mRNA-LNP (2 μg, i.v., single dose) allows total luminescent flux in C57BL/6 mice^[3].
Firefly luciferase mRNA-LNP (1 μg, i.m., on day 1 and day 21) is formulated with either ALC-0315 or SM-102, and SM-102 has 60% higher expression level of luciferase protein than ALC-0315 and cKK-E12 in BALB/c mice^[4].
Firefly luciferase mRNA-LNP (5-20 μg, i.m., single dose) induces activation of Aif1 in the hypothalamus but not in the prefrontal cortex of adult Balb/c male mice^[5].
Firefly luciferase mRNA-LNP (5 μg, i.m./i.v./i.p./i.t., single dose) results in a large portion of the luciferase activity as well as high levels of protein production in the liver, and significant bioluminescent signal in lungs and muscles of BALB/c mouse model^[6].
Firefly luciferase mRNA-LNP (5 μg, i.d./s.c., single dose) results in protein production only at the site of injection in BALB/c mouse model^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c mice aged 6 weeks^[1]
Dosage:	0.1, 1.0, 5.0 μg
Administration:	Intradermal injection (i.d.)/Intraperitoneal injection (i.p.)/Subcutaneous injection (s.c.)/Intramuscular injection (i.m.)/Intravenous injection (i.v.)/Intratracheal injection (i.t.)
Result:	Could not measure signal when mice were injected with 0.1 μg of mRNA-LNPs. Resulted in the highest amount of peak protein production and the shortest duration of expression with intravenous delivery. Did not result in measurable luciferase expression in the liver or other anatomical sites with subcutaneous delivery. Resulted in the longest duration of translation with intramuscular and intradermal delivery. Allowed saturation of the uptake or translational capacity of the intradermal space with intradermal delivery. Observed linear dose response with intravenous injection. Led to similar levels of peak translation at 4 h post injection with all three doses, but the increased doses extended the duration of translation from 5 (1.0 μg) to 10 (5.0 μg) days.

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Firefly luciferase mRNA-LNP]

輸送条件

Shipping with dry ice.

保管条件

-80°C

純度とドキュメンテーション

Select Batch:

データシート (270 KB) SDS (251 KB)

COA (240 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Tenchov, R., et al., (2021). Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS nano, 15(11), 16982-17015. [Content Brief]

[2]. Xu YZ, et al. Promoter deletion analysis using a dual-luciferase reporter system. Methods Mol Biol. 2013;977:79-93. [Content Brief]

[3]. El-Mayta, R., et al., (2023). Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing. Journal of visualized experiments: JoVE, (191), 10.3791/64810. [Content Brief]

[4]. Zhang, L., et al., (2023). Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ vaccines, 8(1), 156. [Content Brief]

[5]. Kirshina, A. S., et al. (2022), "Effects of various mRNA-LNP vaccine doses on neuroinflammation in BALB/c mice", Bulletin of RSMU, no. 6, p. 119–125.

[6]. Pardi, N., et al., (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of controlled release: official journal of the Controlled Release Society, 217, 345–351. [Content Brief]